Consistently, Chantal et al suggested CRYAB as a useful biomarker to help fine‐tune treatment in head and neck squamous cell carcinoma, possibly by targeting CRYAB‐mediated cell motility.9 Obviously, these findings provide evidence delineating the pivotal role of CRYAB in cancer invasion and metastasis. This evidence concerns the gene CRYAB and head and neck squamous cell carcinoma.